Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline

Maastricht, The Netherlands, 2nd November 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO). […]

Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer

Maastricht, The Netherlands, 25th October 2018 – Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for the treatment of cancer and other diseases, announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer. CPC634 is a new drug […]